January 30, 2023
Novo Nordisk Pharma’s diabetes drug semaglutide cleared a key health ministry panel on January 27 for the treatment of obesity. Along with a pediatric label expansion for Pfizer’s sedative Precedex (dexmedetomidine), semaglutide is now expected to be approved as early...read more